Baolai: Announcement on the suspension of trading and share conversion of Baolai convertible bonds
Securities code: 300246 Securities abbreviation: Baolai Announcement number: 2026-049 Bond code: 123065 Bond abbreviation: Baolai convertible bonds
Guangdong Baolaite Medical Technology Co., Ltd.
Announcement on the suspension of trading and share conversion of Baolai Convertible Bonds
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
Bond code: 123065
Bond abbreviation: Baolai Convertible Bond
Convertible bonds trading suspension and equity conversion time: trading will be suspended from the opening of the market on August 3, 2026 (Monday), and equity conversion will be suspended during the suspension period
1. Basic information about bonds
It was reviewed and approved by the 8th review meeting of the GEM Listing Committee of the Shenzhen Stock Exchange in 2020, and approved for registration by the China Securities Regulatory Commission’s Zhengjian Keke [2020] No. 1831. Guangdong Baolaite Medical Technology Co., Ltd. (hereinafter referred to as the "Company") issued 2.19 million convertible corporate bonds to unspecified objects on September 4, 2020, with a face value of RMB 100 each, and a total issuance of RMB 219 million.
The company's 219 million yuan convertible corporate bonds have been listed for trading on the Shenzhen Stock Exchange since September 24, 2020. The bond is referred to as "Baolai Convertible Bonds" and the bond code is "123065".
The starting and ending dates for the conversion of convertible corporate bonds: March 11, 2021 to September 3, 2026 (if it is postponed to the first working day after a statutory holiday or rest day, no additional interest will be accrued on the interest payment during the postponement period)
2. Reasons for suspension of trading and suspension of share conversion of Baolai Convertible Bonds
The company's controlling shareholder is planning a change of control. As there are still uncertainties in relevant matters, in order to protect the interests of investors and avoid significant impact on the company's securities transactions, in accordance with the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 6 - Suspension and Resumption of Trading" and other relevant regulations, the company applied to the Shenzhen Stock Exchange for the company's stocks (securities abbreviation: Baolai, stock code: 300246) and convertible corporate bonds (bond abbreviation: Baolai Convertible Bonds, bond code: 123065) Securities code: 300246 Securities abbreviation: Baolai Announcement number: 2026-049 Bond code: 123065 Bond abbreviation: Baolai convertible bonds
Trading will be suspended from the opening of the market on August 3, 2026 (Monday), and the suspension is expected to last no more than 2 trading days. For details, please refer to the "Trading Suspension Announcement Regarding the Planning of Changes in the Company's Control" (Announcement Number: 2026-048) issued by the company on the cninfo.com on the same day.
According to the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 15 - Convertible Corporate Bonds"
Article 35 stipulates: “When the trading of a listed company’s stocks is suspended or resumed, trading of its convertible bonds shall be suspended or resumed at the same time and the conversion of shares shall be suspended or resumed.” Therefore, during the trading suspension period of "Baolai Convertible Bonds", the conversion of the company's convertible corporate bonds "Baolai Convertible Bonds" into shares is suspended. "Baolai Convertible Bonds" bondholders are kindly requested to pay attention.
3. Other instructions
The company will perform its information disclosure obligations in strict accordance with the relevant provisions and requirements of relevant laws and regulations based on the progress of the above matters. After the above matters are determined, the company will issue relevant announcements in a timely manner and apply for the resumption of trading and share conversion of the company's convertible corporate bonds.
Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Guangdong Baolaite Medical Technology Co., Ltd.
July 31, 2026